Australia: Vectus Biosystems wins the "Medtech & Pharma" category in the Australian Technologies Competition
Last Updated: 6 December 2016

Shelston IP congratulates Australian biotechnology company Vectus Biosystems on winning the 'Medtech & Pharma' category in the Australian Technologies Competition (ATC), announced recently at a gala dinner in Sydney.

The Competition recognises Australia's best technology companies with global potential, and provides assessment, mentoring, profile and promotion for the winners via a bespoke accelerator program.

Vectus Biosystems is a research-based drug discovery company, developing and licensing medicines. The company has developed a library of more than 1,000 small molecules with anti-hypertensive and anti-fibrotic properties.

Fibrotic disease contributes to more than 40 per cent of deaths worldwide, a figure that includes deaths caused by atherosclerosis, the biggest killer in the developed world, as well as diseases affecting the lung, liver and kidney, among others. Treatments for fibrotic diseases represent a major unmet clinical need, and where medicines exist, they only slow the progression of disease. In contrast, Vectus Biosystems' compounds have been shown to reverse fibrosis in preclinical models.

Vectus Biosystems' technology is based on the discovery by Dr Karen Duggan in 2003 that a naturally occurring molecule in the human body was capable of reversing fibrosis caused by hypertension and other chronic diseases such as diabetes.

In 2005 Vectus Biosystems was formed to take Dr Duggan's discovery through to an orally deliverable drug. Today, Vectus Biosystems holds a large number of patents covering various compounds and their use in the treatment of a wide range of fibrotic conditions.

Shelston IP is proud to have been assisting Vectus Biosystems since its inception.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Gareth Dixon
By Tracey Murray, Claire McDowall, David Mason
By Jack Redfern
By Nathan Sinclair, Sean McManis
By Sean McManis
By Gareth Dixon
By Grant Shoebridge
By Matthew Ward
By Peter Treloar
By Serena White DPhil, Jacinta Flattery-O'Brien
Tools
Print
Font Size:
Translation
Channels